Our passion is to develop important, disease-modifying therapies for devastating pulmonary diseases – and Cystic Fibrosis is the first target on our list.

We are building a dedicated team of scientists, clinical staff, management and advisors with the skills and vision to make this a reality.

John Taylor

President & CEO

John is the founding CEO of Spyryx, leading the effort to form the Company into a therapeutic development organization targeting severe pulmonary indications. This entrepreneurial role relies heavily on his prior experience in biopharmaceutical business and corporate development, where he was responsible for execution of transactions valued in excess of $500 million. In addition to Spyryx, John has provided leadership to several other biopharmaceutical start-ups, including JUNCTIONRx, a company he founded to pursue orphan drug development.

Previously, John was Vice President of Corporate Development at Synageva BioPharma (acquired by Alexion Pharmaceuticals), a biotechnology company focused on protein therapeutics for rare diseases, which he helped to take public via a reverse merger with Trimeris. Prior to joining Synageva, John was the Vice President, Business Development for Javelin Pharmaceuticals, a clinical and commercial stage company developing treatments for acute pain. Earlier in his career John held positions of increasing responsibility in licensing and business development, marketing, and sales with Eurand Pharma, Sarnoff Corporation, Amersham Pharmacia Biotech and BioWhittaker.

John received his BS in Biological Sciences from Clemson University and holds an MS in Technology Management from the Wharton School of Business at the University of Pennsylvania.

Alistair Wheeler, MD MFPM

Chief Medical Officer

Alistair leads the Company’s clinical development, medical affairs and regulatory strategy functions. He is a pulmonologist with nearly 35 years of global drug development experience, including work across all phases of development with both small molecules and biologics. He has been personally responsible for over 30 INDs/CTAs and had key roles in the filing of nine successful marketing applications with regulatory agencies worldwide. A large majority of this work has been focused in the respiratory field, developing products for nasal allergy, rhinitis, asthma, COPD, and pneumonia. Additionally, Alistair’s family has a connection to Cystic Fibrosis that fuels his passion to make a meaningful impact on this disease.

Prior to joining Spyryx, Alistair was the Global Head of Clinical Development, Respiratory Medicine and Biotherapeutics at Sunovion Pharmaceuticals, where he was responsible for leading the clinical development of SUN-101 for COPD from Phase 2 to successful NDA filing. He also supported clinical expansion for Sunovion’s approved products in multiple therapeutic areas. Before Sunovion, Alistair was Senior Director, Clinical Research at Cubist Pharmaceuticals, heading the clinical research function for development programs in infectious disease and cardiovascular surgery, as well as leading the clinical support for marketed products. Alistair’s earlier clinical development and medical affairs experience included positions in both the US and Europe at Avant Immunotherapeutics, Astra USA, Hoffmann-LaRoche, and Glaxo.

Alistair earned his MD from the Royal London Hospital Medical College and his MFPM from the Royal College of Physicians. He is a member of the American Thoracic Society and former vice president of the American Academy of Pharmaceutical Physicians.

Timm Crowder, PhD

SVP, Technical Operations

Timm’s responsibilities include Spyryx’s technology and preclinical product development efforts, the manufacturing supply chain and quality system for Spyryx’s product candidates, and oversight of Spyryx’s intellectual property portfolio. He is an inhalation and manufacturing technology expert credited with 10 issued patents on inhalers and powder filling systems and more than 25 publications, book chapters and international presentations relating to aerosol drug delivery, inhaler design, powder filling, and product formulation and characterization.

He came to Spyryx from GlaxoSmithKline where he was most recently Director of Advanced Manufacturing Technology, leading innovation in the areas of aerosol and dry powder inhaler release testing, technology enhanced manufacturing strategies, electronic inhaler and particle engineering technologies. Earlier in his tenure at GSK, he contributed to the development of manufacturing systems and quality-by-design for GSK’s current asthma and COPD products. Prior to GSK, Timm was co-founder and Chief Technology Officer of Oriel Therapeutics, an inhaler technology company launched to commercialize device designs he developed during his graduate research. Oriel was subsequently acquired by Sandoz Pharmaceuticals.

Timm earned his PhD in Biomedical Engineering from UNC-Chapel Hill and has degrees in Physics from North Carolina State University and Davidson College.